DEQING, China, March 28, 2019 / B3C newswire / -- Shuwen Biotech announces that Tasly Pharmaceutical Group has tapped Shuwen Biotech for clinical services and proprietary diagnostics for its oncology drug candidates.
“With the shifting economic macro-environment globally, the need for cost-saving, innovative and personalized diagnostics is more than ever before. We at Shuwen aim to add value not only to committed innovators in the pharmaceutical space like Tasly, but ultimately to all patients in need of healthcare treatments,” commented Jay Z. Zhang, Chairman and CEO of Shuwen Biotech.
The two companies plan to use Shuwen’s established companion diagnostic development team and CAP-accredited reference labs to drive clinical outcomes and ultimately deliver the most innovative and life-saving solutions to patients and healthcare professionals globally.
Established in 1994, Tasly is one of the largest Chinese pharmaceutical companies. Tasly offers a wide variety of pharmaceuticals and traditional Chinese medicines for treating diseases ranging from cardiovascular diseases, diabetes, to cancer. With a turnover of 4 billion US dollars and more than 10,000 employees, Tasly is listed on the Shanghai Stock Exchange.
About Shuwen Biotech
Shuwen Biotech is a China-based diagnostic company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, BioNTech, Sphingotec among others in the form of exclusive licensing of first-in-class diagnostic technologies and patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen has also developed innovative and quality companion diagnostics and provided central lab testing services to leading pharmaceutical developers. Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards in order to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.
Published by B3C newswire and shared through Newronic®